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Abstract
Infections due to Escherichia coli producing extended-spectrum b-lactamase (ESBL) or CMY-type b-lactamase (CMY) are increasingly
observed in non-hospitalized patients. The origin of these organisms is uncertain, but retail meat contaminated with E. coli may be a
source. In the present study, clinical information and strains collected from patients infected or colonized with ESBL-producing and
CMY-producing E. coli at hospitals in Pittsburgh, USA and Seville, Spain were investigated. Retail meat purchased in these cities was also
studied for the presence of these organisms. Twenty-ﬁve and 79 clinical cases with ESBL-producing E. coli and 22 cases and one case
with CMY-producing E. coli were identiﬁed in Pittsburgh and Seville, respectively. Among them all, community-acquired and healthcare-
associated cases together constituted 60% of the cases in Pittsburgh and 73% in Seville. Community-acquired cases were more common
in Seville than in Pittsburgh (49% vs. 13%; p <0.001). ESBL-producing and CMY-producing E. coli isolates were commonly recovered
from the local retail meat. In particular, 67% (8/12) of retail chickens in Seville and 85% (17/20) of those in Pittsburgh contained ESBL-
producing and CMY-producing E. coli isolates, respectively. Among the ESBL-producing isolates, CTX-M and SHV were the most com-
mon ESBL types in both clinical and meat isolates. Approximately half of the ESBL-producing and CMY-producing E. coli isolates from
meat belonged to phylogenetic groups associated with virulent extra-intestinal infections in humans. Community and healthcare environ-
ments are now signiﬁcant reservoirs of ESBL-producing and CMY-producing E. coli. Retail meat is a potential source of these organisms.
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Introduction
Escherichia coli is a leading cause of community-acquired infec-
tions, especially urinary tract infections. In E. coli, resistance to
oxyimino-cephalosporins, such as ceftriaxone and ceftazidime,
occurs by production of extended-spectrum b-lactamases
(ESBLs) and plasmid-mediated AmpC-type b-lactamases [1].
ESBLs and plasmid-mediated AmpC-type b-lactamases in E. coli
were ﬁrst noted in the 1980s [2,3], and have been associated
with hospital-acquired infections. In E. coli, CMY-type b-lac-
tamase (CMY) is the most commonly encountered plasmid-
mediated AmpC-type b-lactamase worldwide [4].
Although it is conventionally perceived as a nosocomial
pathogen, ESBL-producing E. coli has emerged as a commu-
nity pathogen in many parts of the world [5]. Community-
acquired cases are largely caused by E. coli that produces
CTX-M-type ESBLs [5]. Recent reports suggest that CMY-
producing E. coli may cause community-acquired infections as
well [6–8]. The spread of ESBL-producing and CMY-produc-
ing E. coli outside of the hospital environment may compro-
mise the usefulness of penicillins and cephalosporins for
infections such as complicated urinary tract infections and
bacteraemia [7–12]. In addition, these E. coli isolates often
have co-resistance to other classes of antimicrobials, medi-
ª2009 The Authors
Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases
ORIGINAL ARTICLE 10.1111/j.1469-0691.2009.03001.x
ated by other resistance mechanisms (e.g. aminoglycosides,
trimethoprim–sulphamethoxazole and ﬂuoroquinolones) [1].
One potential source of resistant E. coli isolates causing
infection in the community is food that we eat. Some food
animals, including chickens, turkeys, pigs and cattle, may be
colonized by ESBL-producing and CMY-producing E. coli and
have been considered as potential sources of these organ-
isms that cause community-acquired diseases [13].
In the present study, we sought to systematically evaluate
clinical infection with these organisms, using rigorous deﬁni-
tions of the place of acquisition, and to identify these organisms
from retail meat purchased locally during the same time period.
Patients and Methods
Laboratory surveillance of ESBL-producing and
CMY-producing E. coli
Prospective laboratory-based surveillance was conducted
from September 2006 to March 2007 to identify all cases of
ESBL-producing and CMY-producing E. coli infection or colo-
nization at the University of Pittsburgh Medical Center (Pres-
byterian-Shadyside Campus), Pittsburgh, USA and Hospital
Universitario Virgen Macarena, Seville, Spain. The University
of Pittsburgh Medical Center (Presbyterian-Shadyside Cam-
pus) is a 1300-bed tertiary teaching hospital with afﬁliated
outpatient clinics. Hospital Universitario Virgen Macarena is
a 950-bed tertiary teaching hospital with afﬁliated outpatient
clinics and primary-care centres. ESBL production was
screened for and conﬁrmed by the disk diffusion method
deﬁned by the CLSI [14]. For isolates that were non-suscep-
tible (intermediate or resistant) to ceftriaxone and had nega-
tive conﬁrmatory test ﬁndings for ESBL production, PCR
analysis was conducted to identify plasmid-mediated AmpC-
type b-lactamases, including CMY [15].
Study sample and data collection
The study was approved by the Institutional Review Boards
of the University of Pittsburgh and Hospital Universitario
Virgen Macarena, which waived the need to obtain written
informed consent, owing to the observational nature of the
study. Computerized medical and laboratory records were
reviewed to document the place of acquisition of infection
[16]. The same patient could be re-enrolled only when a
positive culture was identiﬁed ‡30 days from the initial en-
rolment. A hospital-acquired case was deﬁned as a positive
culture obtained from a patient who had been hospitalized
for ‡48 h. A healthcare-associated case was deﬁned as a
positive culture obtained from a patient at the time of hospi-
tal admission or <48 h after admission if the patient fulﬁlled
any of the following criteria: (i) received intravenous therapy
at home, received wound care or specialized nursing care
through a healthcare agency, family, or friends, or had self-
administered intravenous medical therapy £30 days before
enrolment; (ii) attended a hospital or haemodialysis clinic or
received intravenous chemotherapy £30 days before enrol-
ment; (iii) was hospitalized in an acute-care hospital for
‡2 days in the 90 days before enrolment; or (iv) resided in a
nursing home or long-term-care facility [17]. A community-
acquired case was deﬁned as one in which a positive culture
was obtained from a patient at the time of hospital admission
or <48 h after admission and that did not meet the criteria
for a healthcare-associated case. Complementary clinical data
for patients from Pittsburgh have been published elsewhere [7].
Statistical analysis
Categorical variables were compared using the chi-squared
test. SPSS software (version 13.0; SPSS, Chicago, IL, USA)
was used for the analyses.
Culturing of retail meat
Chicken, turkey, pork and ground beef were purchased from
local supermarkets at least every 2 weeks in metropolitan
Pittsburgh and Seville during the study period. After immedi-
ate transport of the samples to the research laboratory on
ice, approximately 25 g of each sample was suspended in buf-
fered peptone broth with the use of a sterile technique, and
homogenized manually or with the use of a stomacher. After
overnight incubation at 37C, an aliquot of the broth was
plated on MacConkey agar plates containing 1 mg/L cefotaxime
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FIG. 1. Distribution of extended-spectrum b-lactamase (ESBL)-pro-
ducing or CMY-type b-lactamase (CMY)-producing Escherichia coli
cases according to the place of acquisition at both study sites.
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or ceftazidime and further incubated overnight. Lactose-fer-
menting colonies were identiﬁed as E. coli using standard bio-
chemical tests. Production of ESBL was conﬁrmed by
observing ‡5 mm of growth inhibition around a ceftazidime-
containing or cefotaxime-containing disk in the presence of
clavulanic acid on a Mueller–Hinton agar plate [14]. The col-
onies with negative conﬁrmatory test ﬁndings for ESBL pro-
duction were tested for the presence of plasmid-mediated
AmpC-type b-lactamase genes as described above.
Molecular typing and genetic analyses
For all ESBL-producing and CMY-producing isolates of both
clinical and food origin, PCR analyses to determine the type
of ESBL gene carried by each isolate were performed. Primer
sets to detect TEM-type, SHV-type and CTX-M-type ESBL
genes as well as CMY genes were used [15,18]. Positive
results were conﬁrmed by sequencing of the products. In
addition, we determined the phylogenetic groups of the
E. coli clinical isolates and those of food origin by multiplex
PCR analysis [19]. To determine the genetic relatedness of
the study isolates, pulsed-ﬁeld gel electrophoresis analysis
was performed, using XbaI as a restriction endonuclease, and
electrophoresing the genome on a CHEF III DR system (Bio-
Rad, Hercules, CA, USA), on all isolates, as described previ-
ously [7]. Cluster analysis was performed by using the
unweighted pair group method based on Dice coef-
ﬁcients. The results were interpreted according to the criteria
proposed by Tenover et al. [20].
Results
In Pittsburgh, 2583 E. coli isolates were identiﬁed during the
study period. Of these, 1183 (46%) were obtained from
outpatient locations. In Seville, 2606 E. coli isolates were
identiﬁed. Of these, 2062 (79%) were obtained from outpa-
tient locations.
In Pittsburgh, 47 cases with ESBL-producing and CMY-
producing E. coli were identiﬁed and enrolled. Eighty cases
were identiﬁed and enrolled in Seville. They represented
cases from a total of 125 patients, as two patients were
enrolled for two separate episodes. Urinary tract and blood
were the most common sites, accounting for 95 cases (75%)
and 21 cases (14%), respectively. Other less frequent sites of
infection included the respiratory tract (six; 5%), wounds
(three; 2%), and others (two; 2%). The places of acquisition
and types of b-lactamase produced by the E. coli isolates are
summarized in Table 1 and Fig. 1. At both sites, among the
hospital-acquired and healthcare-associated isolates, the
majority of E. coli isolates produced either CTX-M-type or
SHV-type ESBLs or CMYs. In Pittsburgh, the community-
acquired isolates produced CTX-M-type ESBLs or CMYs. In
Seville, most community-acquired isolates produced either
CTX-M-type or SHV-type ESBLs.
We conducted 20 and 12 independent meat samplings in
Pittsburgh and Seville, respectively. These involved seven
local supermarkets in Pittsburgh and ten in Seville. Fig. 2
summarizes the results. ESBL-producing E. coli was frequently
isolated from retail meat purchased in Seville. In Seville, eight
(67%), seven (58%), three (25%) and one (9%) chicken, tur-
key, pork and ground beef samples, respectively, yielded a
total of 55 clonally unrelated ESBL-producing E. coli isolates.
They produced either CTX-M-type ESBLs (CTX-M-9 group,
six isolates; CTX-M-1 group, four isolates; overall, 18%) or
SHV-type ESBLs (SHV-12, 45 isolates; 82%). No CMY-pro-
ducing E. coli isolate was identiﬁed from retail meat in Seville.
In contrast, in Pittsburgh, only one chicken sample (and none
of the other meat types) grew ESBL-producing E. coli, which
TABLE 1. Distribution of extended-
spectrum b-lactamase (ESBL)-pro-
ducing and CMY-type b-lactamase
(CMY)-producing Escherichia coli
according to the place of acquisi-
tion and the b-lactamase types
Seville Pittsburgh
No. of isolates ESBL/CMY families No. of isolates ESBL/CMY families
Hospital-acquired 22 CTX-M-1 group: 9 18 CTX-M-9 group: 5
CTX-M-9 group: 5 SHV-7: 1a
SHV-12: 8 CMY-2/32/33: 11
Unidentiﬁed: 2
Healthcare-associated 19 CTX-M-1 group: 4 22 CTX-M-1 group: 5
CTX-M-9 group: 8 CTX-M-2 group: 1
SHV-12: 6 CTX-M-9 group: 2
Unidentiﬁed: 1 SHV-7/12: 6
TEM-137: 1
CMY-2: 7
Community-acquired 39 CTX-M-1 group: 7 6 CTX-M-1 group: 3
CTX-M-9 group: 15 CMY-2: 3
SHV-12: 16
CMY-4: 1
Data are expressed as number of cases. The site of acquisition could not be determined for one CMY case in
Pittsburgh.
aThis isolate also produced CTX-M-type ESBL.
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produced CTX-M-1 group ESBLs. However, CMY-2-produc-
ing E. coli isolates were identiﬁed in 17 (85%), 14 (70%), two
(10%) and one (5%) chicken, turkey, pork and ground beef
samples, respectively, in Pittsburgh.
Clonality was not observed among isolates from patients
and retail meat at either site, except for the ESBL-producing
E. coli isolate identiﬁed in a retail chicken product in Pitts-
burgh. This isolate showed a pulsed-ﬁeld gel electrophoresis
pattern indistinguishable from that of an isolate identiﬁed in
a healthcare-associated patient. Among the E. coli clinical iso-
lates and those of food origin from both sites, membership
in a virulence-associated phylogenetic group (group B2 or D)
of available isolates was similar for ESBL-producing E. coli
(54/103 (52%) vs. 25/56 (45%), respectively). For CMY-pro-
ducing E. coli, this was higher in clinical isolates than in meat
isolates (21/23 (91%) vs. 17/34 (49%), respectively).
Discussion
In this analysis of ESBL-producing and CMY-producing E. coli,
we observed a predominance of community-acquired and
healthcare-associated cases at teaching hospitals in Pittsburgh
and Seville. The occurrence of infections due to ESBL-pro-
ducing and CMY-producing E. coli among community patients
has serious implications for the empirical management of
common infections, and warrants continued surveillance. The
predominance of healthcare-associated acquisition of ESBL-
producing and CMY-producing E. coli in Pittsburgh could be
attributed, at least in part, to recent hospital admission and
residence in nursing homes. Data regarding the prevalence of
colonization with ESBL-producing Enterobacteriaceae among
nursing home residents are scarce. Reports from the 1990s
document colonization rates of 15% at baseline to as high as
46% in an outbreak setting [21,22]. A better understanding
of the transmission dynamics of ESBL-producing and CMY-
producing E. coli within these facilities and between them and
acute-care hospitals is vital for the formulation of effective
infection control strategies.
We isolated E. coli producing ESBLs and CMYs from a
large proportion of retail meat samples in Seville and Pitts-
burgh, respectively. The ESBL and CMY gene contents of the
E. coli isolates of food origin correlated well with the genes
that were locally prevalent in clinical isolates, although we
were surprised by the fact that SHV enzymes were more
frequent than CTX-M enzymes. The importance of SHV-pro-
ducing E. coli isolates as community pathogens has been
recently analysed in Spain [23]. Contamination of retail meat,
especially poultry, with E. coli producing CMYs is well docu-
mented [13,24]. Recovery of ESBL-producing E. coli from
retail meat is less common, but has also been reported [25–
28]. Numerous studies have reported the isolation of E. coli
producing ESBLs and CMYs from food-producing animals
[13,24]. Less is known about whether these animals actually
serve as the source of the organisms causing disease in
humans. Recent studies suggest that antibiotic-resistant E. coli
strains isolated from retail poultry share similar phylogenetic
and virulence markers with contemporary human strains
[29], and that poultry isolates have higher virulence scores
than beef and pork isolates [30]. Also, certain food habits
have been found to be associated with faecal carriage of
ESBL-producing E. coli [31].
Our study has several limitations. First, because the study
was performed at single centres in Pittsburgh and Seville, the
national trend could not be captured at either country to
allow the drawing of strong conclusions of broader public
health relevance. Second, the Pittsburgh site had limited
numbers of specimens from outpatient locations. Third, retail
foods other than meat were not cultured. Finally, we pro-
vided an ecological relationship between contamination of
retail meat and colonization or infection due to ESBL-pro-
ducing and CMY-producing E. coli, but we could not demon-
strate a direct causal relationship.
In summary, the majority of infections due to ESBL-
producing and CMY-producing E. coli were acquired in the
community or in association with the healthcare system but
outside hospitals, both in Pittsburgh and Seville. The majority
of retail poultry samples contained E. coli producing ESBLs or
CMYs at both locales. Our ﬁndings provide further circum-
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FIG. 2. Prevalence of extended-spectrum b-lactamase (ESBL)-pro-
ducing or CMY-type b-lactamase (CMY)-producing Escherichia coli in
retail meat at both sites. The retail chicken product with ESBL-pro-
ducing E. coli in Pittsburgh also grew CMY-producing E. coli (*).
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stantial evidence that retail meat may serve as a source of
ESBL-producing and CMY-producing E. coli isolates, which
may then colonize the human intestine and cause infections,
or serve as donors of ESBL and CMY genes to the human
strains by means of conjugal transfer of resistance plasmids.
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